Vernon Mackie, MD
Hematology-Oncology · Bethesda, MDNPI 1780813147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 35.9% of the total. Reporting peaked in 2021 at $701 and has fallen 66.1% since, to $238 in 2025.
Across 26 payments — averaging $59.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$553
- Incyte Corporation$244
- AstraZeneca$130
- GSK$122
- Sanofi$120
- Exelixis Inc.$119
- plus $253 from 4 others
What the payments were for
- Food & beverage$1,542100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $553 |
| Incyte Corporation | 2 | $244 |
| AstraZeneca | 2 | $130 |
| GSK | 1 | $122 |
| Sanofi | 1 | $120 |
| Exelixis Inc. | 1 | $119 |
| Ipsen Biopharmaceuticals, Inc | 1 | $111 |
| ADC Therapeutics America, Inc. | 1 | $97 |
| Novartis | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OnuregAzacitidine | 13 | $326,949 |
| Lenalidomide | 22 | $316,225 |
| TabrectaCapmatinib Hydrochloride | 11 | $253,874 |
| KisqaliRibociclib Succinate | 16 | $241,607 |
| IbrancePalbociclib | 14 | $224,883 |
| CalquenceAcalabrutinib Maleate | 16 | $223,237 |
| TagrissoOsimertinib Mesylate | 12 | $197,842 |
| VenclextaVenetoclax | 12 | $178,979 |
| JakafiRuxolitinib Phosphate | 14 | $120,199 |
| EliquisApixaban | 46 | $42,423 |
| Abiraterone Acetate | 24 | $37,191 |
| XareltoRivaroxaban | 25 | $17,407 |
| Dexamethasone | 42 | $1,244 |
| Letrozole | 38 | $869 |
| Hydroxyurea | 32 | $779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTabrecta, Kisqali | $23 | $495,48127 claims |
| AstraZenecaCalquence, Tagrisso | $130 | $421,08028 claims |
| E.r. Squibb & Sons, L.L.C.Onureg | $553 | $326,94913 claims |
| Incyte CorporationJakafi | $244 | $120,19914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Bethesda
- Carolyn HendricksBethesda$641
- Xiaoyan WangGreenbelt$4K
- Ravi AnandakrishnanBaltimore$3K
- Philip KonitsFinksburg$2K
- Cheryl AylesworthWheaton$2K
- Alida PodrumarCumberland$0
- May Tun SaungBaltimore$0
- Katherine RappazzoBaltimore$0
- Moonjung JungBaltimore$0
- Manpreet SidhuElkton$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.